NSCLC

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
NCT00866970 | PHASE 2 | INTERVENTIONAL

The purpose of this study is to asses the safety and efficacy of ALD518 in patients with Non-Small Cell Lung Cancer-Related Fatigue and cachexia (weight-loss).

Trial Information
43 Sites
124 Participants
Recruiting
18 Years to 60 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
Rivercity Hospital Research Centre
Auchenflower,Queensland,Australia,4066
Australian Clinical Research Organisation
Kippa Ring,Queensland,Australia,4021
Royal Adelaide Hospital
Adelaide,South Australia,Australia,5000
Palliative Care Launceston General Hospital
Launceston,Tasmania,Australia,7250
Cross Cancer Institute
Edmonton,Alberta,Canada,T6G1Z2
Atlantic Health Sciences Corporation
Saint John,New Brunswick,Canada,E2l4L2
McGill University, Department of Oncology
Montreal,Quebec,Canada,H2W1S6
A. Gvamichava National Cancer Centre
Tbilisi,Georgia,0177
Union Cancer Prevention Centre
Tbilisi,Georgia,0177
Medulla Chemotherapy and Immunotherapy Clinic
Tbilisi,Georgia,0186
Indira Gandhi Institute of Medical Sciences
Patna,Bihar,India
Dr. Kamakshi Memorial Hospital
Pallikaranai,Chennai,India,600100
GKNM Hospital
Pappanaickenpalayam,Coimbatore,India,641037
Curie Manavata Cancer Centre
Nasik,Maharashtra,India,422304
Kidwai Memorial Institute of Oncology
Bangalore,India,560029
Kailash Cancer Hospital and Research Centre
Gujarat,India,391760
IndoAmerican Cancer Institute & Research Center
Hyderabad,India,500034
SEAROC Cancer Centre
Jaipur,India,302013
Orchid Nursing Home
Kolkata,India,700054
Tata Memorial Hospital
Mumbai,India,400012
Shatabdi Hospital
Mumbai,India
Mahavir Cancer Sansthan
Patna,India,801505
Jehangir Clinical Development Centre Pvt. Ltd.
Pune,India,411001
P Research LTD
Tauranga,New Zealand,31-40
Oddzial Chorob Pluc i Leczenia Raka Pluc
Bydgoszcz,Poland,85-326
Oddzial Chemioterapii Szpital Morski
Gdynia,Poland,81-519
II Oddzia Chorob Pluc z Pododdzialem Chemioterapii
Krakow,Poland,31-202
Oddzial II Chemioterapii Specjalistyczny Szpital
Szczecin,Poland,70-891
Professor Dr. Al Trestioreanu Institute
Bucharest,Romania,022328
Professor Dr. I Chiricuta Institute of Oncology and Radiotherapy
Cluj-Napoca,Romania,400015
Oradea Clinical County Hospital Medical Oncology Department
Oradea,Romania,410032
County Hospital Sibiu Medical Oncology Department
Sibiu,Romania,550245
Territorial Clinical Oncology Dispensary
Krasnodar,Krasnodar Territory,Russian Federation,350040
Republic Oncology Dispensary
Ufa,Republic Of Bashkortostan,Russian Federation,450054
Stavropol Territorial Clinical
Pyatigorsk,Stavropol Territory,Russian Federation,357500
City Clinical Hospital No.
Novosibirsk,Russian Federation,630047
SaintPetersburg State Medical University, I.P. Pavlov
Saint-Petersburg,Russian Federation,197022
St. Petersburg City Oncology Dispensary
Saint-Petersburg,Russian Federation,198255
Yaroslavl Regional clinical Oncology Hospital
Yaroslavl,Russian Federation,150054
Institute of Lung Diseases and TB
Belgrade,Serbia,11000
Clinical Hospital Center Bezanijska Kosa
Belgrade,Serbia,11080
Clinical Centre Kragujevac
Kragujevac,Serbia,34000
Institute for Pulmonary diseases of Vojvodina
Sremska,Serbia,21104

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov